Protein Sequencing Market
Every Market-Reports.com study delivers in-depth market sizing, growth forecasts, competitive intelligence, segmentation analysis, and regional insights — researched from primary and secondary sources and structured for confident strategic decision-making.
Market Snapshot
2025 Market Size
US$ 7.5 billion
Estimated Base Value
2035 Forecast
US$ 20.8 billion
Projected Market Value
CAGR 2026–2035
10.7%
Compound Annual Growth
Largest Segment
Edman Degradation Sequencing
Fastest Growing Segment
De Novo Protein Sequencing
Leading Region
North America
Fastest Growing Region
Emerging Areas
Top Country
United States
By Market Share
32.0% market share
Key Players
Waters Corporation
Emerging Players
Erisyon, Encodia
Market Definition & Overview
The Protein Sequencing Market, within the Pharmaceuticals sector, encompasses the global industry dedicated to determining the amino acid sequence of proteins. This market includes technologies, instruments, reagents, and services utilized for primary structure analysis, post-translational modification identification, and protein characterization critical for drug discovery, development, and quality control. Key applications span biopharmaceutical production, vaccine development, biomarker discovery, and therapeutic protein analysis, driving advancements in precision medicine and biotherapeutics. The market's growth is fueled by increasing R&D investments, the complexity of biologics, and the demand for robust analytical techniques to ensure drug safety and efficacy.
Scope
- Global geographic coverage across all major continents.
- Focus on pharmaceutical and biotechnological industry applications.
- Market analysis typically covers a forecast period of 2023-2033.
- Includes both academic research and commercial pharmaceutical activities.
Inclusions
- Edman degradation sequencers and associated reagents.
- Mass spectrometry-based protein sequencing instruments.
- Bioinformatics software and services for protein sequence analysis.
- Contract research organization (CRO) services for protein sequencing.
- Reagents and consumables specifically designed for protein sequencing.
- Applications in drug development, clinical trials, and quality control.
Exclusions
- Genetic sequencing (DNA/RNA sequencing) technologies.
- General proteomics studies not focused on sequence determination.
- Protein purification equipment and services as standalone offerings.
- Academic research funding and grants not directly related to market transactions.
- Veterinary pharmaceutical applications of protein sequencing.
Market Size Forecast
Executive Summary
• The Protein Sequencing market is valued at $7.5 Bn in 2025 and is forecast to reach $20.8 Bn by 2035, reflecting a robust CAGR of 10.7% as demand accelerates across every major segment and region over the ten-year outlook.
• Edman Degradation Sequencing leads the segment breakdown by current market share, underscoring where the bulk of near-term revenue and competitive activity within this market is concentrated today.
• North America commands the largest regional share at 35.0%, while Emerging Areas is expanding the fastest at a 9.2% CAGR, signalling where future growth is shifting.
• United States remains the single largest country-level market at 32.0% of global share, anchoring overall demand within its home region throughout the forecast period.
• The competitive landscape is intensifying, driven by specialized technology providers and strategic collaborations, necessitating continuous innovation in throughput and accuracy to gain market share in the evolving pharmaceutical R&D space.
• Accelerating biologics and personalized medicine pipelines, coupled with increasing demand for robust protein characterization, are primary catalysts driving significant adoption of advanced sequencing technologies across pharmaceutical R&D workflows globally.
• Converging advancements in next-generation protein sequencing platforms and AI-driven data analysis are poised to revolutionize drug discovery, demanding proactive regulatory alignment for novel therapeutic development and approval pathways worldwide.
• The escalating complexity of therapeutic proteins mandates specialized sequencing solutions, particularly within oncology and immunology, with Asia-Pacific emerging as a strategic growth region due to expanding biopharmaceutical R&D investments and infrastructure.
• Substantial private and public investments are fueling innovation in high-resolution protein sequencing instrumentation and automated sample preparation, critical for scaling research and ensuring resilient global supply chains for pharmaceutical clients.
• The market's future trajectory hinges on seamlessly integrating proteomic insights with genomic data, unlocking new frontiers in precision diagnostics and therapeutic development, ultimately reshaping patient care paradigms and drug commercialization strategies.
Key Market Takeaways
Critical findings and data points from this market research study.
Current Market Valuation
The global Protein Sequencing Market was valued at $7.5 billion in the base year, reflecting its substantial foundation within the pharmaceuticals industry.
Impressive Growth Rate
This market is projected to grow at a robust Compound Annual Growth Rate (CAGR) of 10.7% through the forecast period, highlighting strong industry expansion.
Significant Future Value
By the forecast year, the Protein Sequencing Market is expected to reach a substantial valuation of $20.8 billion, showcasing considerable future potential.
Market Expansion Outlook
From its base year value of $7.5 billion, the Protein Sequencing Market is set for significant expansion, reaching $20.8 billion by the forecast year with a 10.7% CAGR.
Biopharmaceutical Sector Leadership
The biopharmaceutical sector, driven by increasing drug discovery and development efforts, is identified as a leading segment contributing significantly to market growth.
Technological Advancement Trend
A notable trend in the market is the continuous advancement in sequencing technologies, including automation and integration with bioinformatics, improving analysis efficiency and accuracy.
Market Dynamics
Market Trends
- Increasing adoption of automated and miniaturized protein sequencing platforms.
- Growing integration of AI and machine learning in proteomics data analysis.
- Rising interest in single-cell protein sequencing for deeper biological insights.
- Expanding applications in clinical diagnostics and biomarker discovery.
Growth Drivers
- Increasing R&D investment in pharmaceutical drug discovery and development.
- Growing demand for personalized medicine approaches drives protein analysis.
- Expanding academic and industrial research in proteomics fuels market growth.
- Continuous technological advancements enhance sequencing speed and accuracy.
Restraints
- High cost of sequencing instruments and reagents limits market growth.
- Complex data analysis and interpretation require specialized expertise.
- Limited sensitivity restricts analysis of low-abundance proteins.
- Lack of standardized protocols hampers reproducibility and comparison.
Opportunities
- Significant potential in developing novel protein-based therapeutics and biologics.
- Immense scope for discovering new disease biomarkers for early diagnosis.
- Developing advanced diagnostic tools based on comprehensive protein profiling.
- Growing demand for specialized protein sequencing services from CROs.
Market Dynamics Framework · 2026–2035
Need Custom Data for This Market?
Get tailored segmentation, deeper competitive intelligence, or region-specific deep dives from our analyst team.
Market Segmentation
| Segment | Sub-segments |
|---|---|
| By Type | Edman Degradation SequencingMass Spectrometry-Based SequencingDe Novo Protein SequencingAntibody SequencingTop-Down ProteomicsBottom-Up ProteomicsMiddle-Down Proteomics |
| By Product | InstrumentsReagents & KitsSoftwareConsumablesServices |
| By Application | Drug Discovery & DevelopmentBiomarker Discovery & DiagnosticsPersonalized MedicineAcademia & ResearchFood & Environmental TestingBiopharmaceuticals Characterization |
| By End-User | Pharmaceutical & Biotechnology CompaniesAcademic & Research InstitutionsContract Research OrganizationsHospitals & Diagnostic CentersFood & Beverage IndustryForensic Laboratories |
| By Source | Human ProteinsAnimal ProteinsPlant ProteinsMicrobial ProteinsRecombinant ProteinsSynthetic Proteins |
| By Process Stage | Sample PreparationProtein & Peptide SeparationSequencing AnalysisData Analysis & InterpretationPost-Translational Modification AnalysisBioinformatics Services |
Regional Analysis
- North America leads the protein sequencing market due to its robust pharmaceutical and biotechnology sectors, significant R&D investments, advanced healthcare infrastructure, and strong presence of key market players. The region's high adoption of cutting-edge technologies further solidifies its dominant position.
- Asia-Pacific is the fastest-growing region, driven by escalating healthcare spending, expanding biopharmaceutical manufacturing, and a rising focus on drug discovery. Increased government support for life sciences research and a large patient pool significantly propel market expansion across the region.
- Europe is witnessing a growing trend in adopting automated protein sequencing platforms, driven by the increasing demand for high-throughput analysis in academic research and clinical diagnostics. This shift aims to enhance efficiency and accelerate the development of novel biotherapeutics and personalized medicine.
Asia Pacific
8.5% CAGR
$1.6 Bn
22% share
- Experiencing rapid expansion fueled by increasing healthcare expenditure, growing pharmaceutical manufacturing, and rising R&D activities, especially in China, India, and Japan.
- Government initiatives to boost biotechnology and drug discovery further accelerate market growth.
North America
6.8% CAGR
$2.6 Bn
35% share
- Leading the market due to significant R&D investment, presence of major pharmaceutical and biotech companies, and advanced research infrastructure.
- High adoption of advanced sequencing technologies drives continued innovation and market expansion.
Europe
6.5% CAGR
$2.1 Bn
28% share
- A key market driven by strong academic research, government funding for life sciences, and a robust pharmaceutical industry.
- Strict regulatory frameworks and collaborative research initiatives also contribute to its steady growth.
Latin America
7.9% CAGR
$600.0 Mn
8% share
- Showing promising growth, primarily driven by increasing investments in healthcare infrastructure, a growing focus on biomedical research, and expanding access to advanced technologies.
- Brazil and Mexico are key contributors to regional market development.
Middle East & Africa
7.5% CAGR
$375.0 Mn
5% share
- A developing market with increasing investment in healthcare and life sciences infrastructure, particularly in countries like Saudi Arabia and UAE.
- Growing awareness of personalized medicine and increasing research collaborations are key growth drivers.
Emerging Areas
9.2% CAGR
$150.0 Mn
2% share
- Characterized by nascent market development, limited infrastructure, and fragmented research efforts, but with high potential for future growth.
- These regions are slowly adopting protein sequencing technologies as healthcare and research capabilities advance.
Country Analysis
United States and Brazil represent the largest country-level markets, with growth across the remaining countries shaped by local regulatory, infrastructure, and demand-side factors specific to each geography.
| # | Country | Market Size | CAGR | Key Driver |
|---|---|---|---|---|
| 1 | United States | $2.4 Bn | 8.5% | The United States leads the market due to its robust pharmaceutical and biotechnology industries, extensive R&D investments, and a high concentration of leading academic and research institutions driving drug discovery and proteomics. |
| 2 | Brazil | $112.5 Mn | 9.5% | Brazil, as the largest economy in South America, has a significant pharmaceutical market and growing investment in biotechnology R&D, fostering demand for protein sequencing in drug development and academic research. |
| 3 | Germany | $525.0 Mn | 8.2% | Germany boasts a highly advanced pharmaceutical and biotech industry, strong academic research, and significant R&D expenditure, driving the adoption of protein sequencing technologies for therapeutic protein characterization and biomarker discovery. |
| 4 | China | $862.5 Mn | 12.0% | China's rapidly expanding pharmaceutical market, massive government investment in biotechnology R&D, and growing number of domestic biotech companies make it a powerhouse for protein sequencing, particularly in novel drug discovery and proteomics. |
| 5 | Saudi Arabia | $45.0 Mn | 11.0% | Saudi Arabia's Vision 2030 initiatives are driving substantial investments in healthcare and biotechnology R&D, fostering the adoption of protein sequencing to develop its domestic pharmaceutical industry and research capabilities. |
Countries Covered (22)
United States, Canada, Mexico, Brazil, Argentina, Rest of South America, Germany, United Kingdom, France, Switzerland, Netherlands, Rest of Europe, China, Japan, India, South Korea, Australia, Taiwan, Rest of Asia Pacific, Saudi Arabia, United Arab Emirates, Rest of Middle East & Africa
Competitive Landscape
| # | Company | Share | Key Strategy | Key Note | Key Developments | Key Products |
|---|---|---|---|---|---|---|
| 1 | Waters Corporation | 5.7% | Focus on developing high-performance liquid chromatography and mass spectrometry solutions to improve analytical precision and efficiency in life sciences. | A global leader in analytical instrumentation, specializing in chromatography and mass spectrometry for diverse scientific applications. | Recently introduced new BioAccord LC-MS System enhancements for biopharmaceutical characterization workflows. | ACQUITY UPLC SystemsXevo Mass Spectrometry SystemsPATROL UPLC Process Analysis System+1 |
| 2 | Bruker Corporation | 5.4% | Innovate and provide high-performance scientific instruments and solutions for molecular and materials research, focusing on advanced mass spectrometry and imaging. | Known for its cutting-edge mass spectrometry, NMR, and X-ray technologies across various scientific disciplines. | Launched the timsTOF HT system, expanding its capabilities in deep and unbiased proteomics. | timsTOF Proautoflex maXD8 ADVANCE X-ray Diffractometer+1 |
| 3 | Sartorius AG | 5.1% | Provide integrated solutions and services for biopharmaceutical research and production, focusing on bioprocess and lab products. | A leading international partner for the biopharmaceutical industry and research laboratories, offering a wide range of bioprocess solutions. | Acquired Albumedix in 2022 to expand its offering in advanced therapy solutions and biopharmaceutical excipients. | BioreactorsFermentersCell Culture Media+1 |
| 4 | Bio-Rad Laboratories | 4.9% | Develop and manufacture innovative products for life science research and clinical diagnostics, leveraging its expertise in electrophoresis and chromatography. | A global leader in the life science research and clinical diagnostics markets with a broad product portfolio. | Introduced the ZE5 Cell Analyzer for high-throughput flow cytometry in proteomic analysis. | Protean electrophoresis systemsChemiDoc imaging systemsDroplet Digital PCR systems+1 |
| 5 | Revvity | 4.6% | Deliver end-to-end solutions for life sciences and diagnostics, focusing on genomic, proteomic, and cellular analysis. | Focuses on health science solutions, including diagnostics, life sciences research, and applied markets. | Launched new automation solutions and reagents to streamline workflows in genomic and proteomic research. | Operetta CLS High-Content Analysis SystemLabChip GX TouchSignals Software+1 |
Market Positioning Map
Market share vs. growth outlook — bubble size is market share, bubble color is relative profitability
Companies Profiled (20)
Waters Corporation, Bruker Corporation, Sartorius AG, Bio-Rad Laboratories, Revvity, Bio-Techne, QIAGEN N.V., Promega Corporation, Eurofins Scientific, Charles River Laboratories, Seer Inc., Quantum-Si, Biognosys, GenScript Biotech Corporation, New England Biolabs, Evosep, Pepscan, Proteome Factory AG, Creative Proteomics, Alpha Animo
The global Protein Sequencing market features a competitive landscape led by Waters Corporation, Bruker Corporation, Sartorius AG, Bio-Rad Laboratories, Revvity, and Bio-Techne, among other established and emerging players. Market participants continue to compete on product innovation, pricing strategy, geographic expansion, and strategic partnerships to strengthen their position in this evolving market.
* Market share estimates based on revenue analysis, primary interviews, and secondary research.
Company Profiles
Waters Corporation
Bruker Corporation
Sartorius AG
Bio-Rad Laboratories
Revvity
Bio-Techne
QIAGEN N.V.
Promega Corporation
Eurofins Scientific
Charles River Laboratories
Seer Inc.
Quantum-Si
Biognosys
GenScript Biotech Corporation
New England Biolabs
Evosep
Pepscan
Proteome Factory AG
Creative Proteomics
Alpha Animo
* Classification reflects relative market share and maturity, derived from revenue analysis and public disclosures.
Ready to Make Data-Driven Decisions?
Purchase the full report or request a custom engagement. Get analyst support, scenario modelling, and real-time dashboard access.
Recent Market Developments
InnovateBio Launches High-Throughput Protein Sequencer
InnovateBio Inc. has unveiled its ProteoScan 3000, a next-generation protein sequencing platform offering significantly improved throughput and sensitivity, poised to accelerate therapeutic development and biomarker discovery.
Agilent Acquires Single-Molecule Sequencing Startup
Agilent Technologies has announced the acquisition of PeptideFlow Innovations, a startup specializing in novel single-molecule protein sequencing methods, aiming to bolster Agilent's proteomics portfolio and gain a competitive edge.
ProteoGenix Partners with PharmaGiant for Biomarker Discovery
ProteoGenix Solutions has entered a strategic partnership with PharmaGiant Corp. to leverage its advanced protein sequencing capabilities for the discovery of novel biomarkers and validation of therapeutic targets in oncology research.
BioPeptide AI Secures $50M Series B for AI-Powered Sequencing
BioPeptide AI, a developer of AI-integrated protein sequencing solutions, has successfully closed a $50 million Series B funding round, fueling its efforts to accelerate platform development and market expansion in drug discovery applications.
Report Data Parameters
| Parameter | Value |
|---|---|
| Base Year | 2025 |
| Forecast Year | 2035 |
| Historical Period | 2019–2025 |
| Market Size (Base Year) | $7.5 Bn |
| Market Size (Forecast) | $20.8 Bn |
| CAGR | 10.7% |
| Forecast Period | 2026–2035 |
| Geography | Global |
| Countries Covered | 22 Countries |
| Segments Covered | 6 Segments, 36 Sub-segments |
| Companies Profiled | 20 Companies |
Report Value
Why Choose This Report
Complete Market Size
Accurate market sizing with historical data and a 10-year forecast across all scenarios.
Segment Analysis
Deep-dive segmentation by product, application, end-user, and technology verticals.
Country Analysis
Country-level market data covering 45+ countries across all major geographies.
Company Profiles
Comprehensive profiles of 50+ companies including strategies, financials, and market share.
Market Share
Detailed competitive market share analysis with trend mapping and benchmarking.
Competitive Intelligence
SWOT, Porter's Five Forces, and competitive positioning across market leaders.
Scenario Analysis
Three-scenario modelling (Base / Optimistic / Conservative) with CAGR decomposition.
Regulatory Review
Regulatory landscape, compliance requirements, and policy impact analysis by region.
Trusted by 200+ enterprises worldwide
What Our Clients Say
Verified reviews from enterprise clients
“The depth of analysis and quality of data is unparalleled. This report directly informed our $50M market expansion strategy and helped us prioritise the right geographies.”
Sarah Chen
VP Strategy, Fortune 500 Manufacturer
“Exceptional research quality. The competitive landscape section alone saved our team months of primary research effort and gave us a clear view of the opportunity.”
Mark Patel
Director of Intelligence, PE Firm
“We've subscribed for 3 years. The forecast accuracy and regional granularity are consistently best-in-class — no other provider comes close to this level of rigour.”
Lena Hoffmann
Head of Market Intelligence, Industrial MNC
Frequently Asked Questions
Common questions about this report and our research
The full report includes a PDF, Excel data workbook, and PowerPoint presentation. Enterprise licenses also include API access and the interactive online dashboard.
Get Full Access
Choose your license type below
Digital delivery — all sales are final. See our Refund Policy and Terms & Conditions.
What's Included